Medicare negotiation of drug prices would stifle the development of much-needed therapies. Curtailing defensive medicine and rolling back excessive regulation would be a better way to control healthcare costs.
Michael Abrams, MA
Advertisement
Co-founder of Numerof & Associates
Articles by Michael Abrams, MA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The ripple effects of Medicare’s maximum fair price with Hiva Pourarsalan, Pharm.D. | AMCP Nexus 2026
2
Targeted therapies for atopic dermatitis reduce hospitalizations and ER visits, but cost is a different story
3
How common is atopic dermatitis in the US? Not nearly as common as other research has shown, according to this study
4
Medicaid can't opt out of gene therapies, so planning matters more, says Katelyn Meyer, Pharm.D. | AMCP Nexus 2026
5